For biotech companies, Medical Affairs can become a pressure point long before a full internal function is in place. As clinical programmes advance, evidence expands and launch planning begins, teams may suddenly need scientific communication, stakeholder engagement, medical education and medical information capabilities at the same time. The right medical affairs consultant can help close these gaps without forcing the company to build every capability internally.

The risk is not simply a lack of capacity. When responsibilities are fragmented across functions or suppliers, scientific priorities can become disconnected from execution, internal experts can be pulled away from higher-value work, and Medical Affairs activities may develop reactively rather than around a clear strategy. For lean biotech organisations, these pressures can intensify quickly as the product moves toward key development or launch milestones.

For companies evaluating the best medical affairs outsourcing partners for biotech, the goal should therefore be more than finding extra hands. The stronger model is to choose a partner that can add the right expertise at the right stage, integrate with the internal team and adapt as scientific, regulatory and operational needs evolve.

How can Billev Pharma East support biotech medical affairs teams?

Biotech companies do not always need to build every Medical Affairs capability internally. What they need is reliable access to experienced Medical Affairs expertise that can expand as scientific priorities, stakeholder needs and product-development milestones change. Billev Pharma East can work as an extension of the internal Medical Affairs team, providing focused support for individual activities or broader ongoing support when additional capacity is required.

Our Medical Affairs offering is built around three closely connected areas: patient journey, medical education and medical inquiries. This allows us to support biotech teams not only with individual deliverables, but with the wider Medical Affairs activities that help translate scientific strategy into practical engagement with healthcare professionals, patients and other relevant stakeholders.

Through our medical education services, we help companies turn identified educational needs into scientifically robust programmes that can be adapted to the relevant audience, therapeutic context and internal capabilities. Our support can range from targeted scientific input to broader programme development and execution, giving biotech companies access to additional expertise without requiring them to build the full capability internally.

We also support medical inquiries and medical information activities, helping companies manage scientific questions from healthcare professionals, patients and other stakeholders in a structured and medically appropriate way. This can be particularly valuable for biotech organisations where internal Medical Affairs teams are small but still need to provide timely, scientifically accurate responses as interest in a product increases.

Our patient journey pharma support adds another strategic layer. By helping teams understand unmet needs, stakeholder interactions, care-pathway gaps and patient experiences, we can support Medical Affairs priorities that are more closely connected to what is happening in clinical practice. Patient journey work can also inform stakeholder engagement, educational priorities and evidence-generation needs.

What differentiates Billev Pharma East is the ability to combine these Medical Affairs capabilities within one flexible partnership. A biotech company may initially need support with a single medical education programme, a defined medical information activity or a patient journey project. As needs evolve, the scope can expand without requiring the company to identify and coordinate several separate providers.

For lean biotech teams, this creates a practical alternative to building every Medical Affairs capability in-house. You retain strategic ownership of your Medical Affairs direction, while Billev Pharma East provides the expertise, capacity and hands-on support needed to move priorities into execution.

If your biotech team needs additional Medical Affairs capacity, Billev Pharma East can provide a scalable support model tailored to your current gaps, product stage and scientific priorities.

What should biotech companies look for in a medical affairs outsourcing partner?

Choosing among the best medical affairs outsourcing partners for biotech requires more than comparing service menus. The first question is whether the partner can understand the scientific context, the product stage and the specific Medical Affairs problem the company is trying to solve.

Relevant expertise should be matched to the work itself. A partner supporting a pre-launch biotech may need to connect scientific strategy, evidence interpretation, stakeholder planning and operational execution, while a post-launch team may require more sustained support for medical information, education or evolving evidence needs. Depending on the programme, capabilities in patient journey mapping can also be valuable when Medical Affairs needs a structured view of diagnostic, referral, treatment and follow-up touchpoints. The partner should also be able to explain how responsibilities, governance, review processes and communication with the internal team will work in practice.

A strong medical affairs consultant should also be able to work across functional boundaries. Medical Affairs frequently interacts with regulatory affairs, pharmacovigilance, clinical development and medical writing, and an outsourcing model becomes more efficient when the external team understands these interfaces rather than treating each activity as a separate workstream.

Finally, biotech companies should assess flexibility. The right partner should be able to provide targeted expertise for a defined need and then scale or reshape support as the programme evolves. This is particularly important for organisations whose resource needs can change quickly around data readouts, regulatory milestones or launch preparation.

When does medical affairs outsourcing make sense for biotech companies?

Medical Affairs outsourcing is most useful when the company has a clear strategic need but does not yet have the internal capacity, specialist expertise or workload to justify building every capability in-house. This often occurs as a biotech moves from clinical development toward launch, enters a new therapeutic area or market, or faces a temporary increase in scientific and stakeholder-facing activity.

Outsourcing can also be valuable when the internal team needs to protect its time for decisions that require company-specific knowledge and leadership. External specialists can support execution-heavy or specialist activities while internal Medical Affairs retains strategic oversight and final accountability for priorities.

The decision should therefore be based on capability gaps rather than company size alone. A larger organisation may outsource a highly specialised workstream, while a smaller biotech may use external support to create access to several capabilities without establishing a large permanent structure. External expertise can also support patient journey optimization when the company needs to translate identified pathway gaps into practical Medical Affairs, education, engagement or evidence-generation priorities. The most effective model is one in which the scope is deliberate, responsibilities are clear and the level of support can change as the programme develops.

Which medical affairs activities can be outsourced?

A biotech company can outsource selected Medical Affairs activities or use an external partner across a broader programme, depending on its internal structure and stage of development. Common areas include scientific and medical content development, medical education, medical information and inquiry handling, evidence synthesis, stakeholder-related planning and project coordination around Medical Affairs deliverables. External specialists can also help generate and interpret patient journey insights to better understand unmet needs, access challenges and stakeholder experiences across the care pathway.

The key is not to outsource by default, but to decide where external expertise creates the greatest value. Activities that require continuous ownership of company strategy, internal decision-making or sensitive organisational knowledge may remain primarily in-house, while specialist or capacity-intensive work can be supported externally. This division should be explicit so that the external team complements the internal function rather than duplicating it.

For biotech companies, a multidisciplinary partner can be particularly useful when an activity touches several functions. Medical inquiries, for example, can have pharmacovigilance implications; scientific materials may require regulatory awareness; and education programmes depend on accurate interpretation of clinical evidence. An integrated model can therefore reduce unnecessary hand-offs and make outsourced support easier to manage.

How can an external medical affairs partner integrate with an internal biotech team?

An external Medical Affairs partner should strengthen the internal biotech team rather than operate as a separate function. Integration begins with clear responsibilities, agreed decision points and practical communication routes so that external work remains connected to the company’s medical strategy and internal review processes.

This is especially important when Medical Affairs activities overlap with regulatory affairs, pharmacovigilance, clinical development or medical writing. A partner that understands these interfaces can coordinate more effectively, identify where additional input is needed and reduce the risk that related activities move forward in isolation. Where relevant, patient journey analysis can bring together scientific evidence and perspectives from different stages of the care pathway to support more focused internal decisions.

The role of an external medical affairs consultant should also be able to evolve. Early support may focus on establishing priorities and translating evidence into a workable Medical Affairs plan. Closer to launch, needs may shift toward medical education, stakeholder-facing scientific communication or medical information. After launch, the balance can change again as new evidence and stakeholder questions emerge.

At Billev Pharma East, this flexible model allows biotech companies to draw on Medical Affairs support alongside wider scientific and regulatory expertise. Our multidisciplinary perspective can also help teams consider how patient journey barriers differ between therapeutic areas and how these differences may influence education, stakeholder engagement and other Medical Affairs priorities. The objective is not to replace the internal team, but to extend its capabilities where additional expertise or capacity can move the programme forward.

How should biotech companies measure the value of medical affairs outsourcing?

The value of Medical Affairs outsourcing should be defined before the work begins. Biotech companies need to be clear about what the external support is expected to improve: faster access to specialist expertise, greater execution capacity, stronger scientific engagement, more consistent medical information, better insight generation or improved coordination across workstreams. Without that starting point, it is easy to measure activity while missing whether the partnership is actually helping the Medical Affairs strategy move forward.

The most useful measures combine quantitative delivery indicators with qualitative measures of impact. Timeliness, agreed deliverables and responsiveness matter, but so do the relevance of scientific outputs, the quality of stakeholder insights, the usefulness of recommendations and the extent to which external work supports internal decision-making. Medical Affairs Professional Society guidance on metrics similarly emphasises that activity counts alone do not capture the full value of Medical Affairs and that qualitative measures should be linked to strategic objectives.

Measurement should also form part of governance rather than being treated as an end-of-project exercise. Regular reviews give the biotech company and its partner an opportunity to confirm priorities, identify emerging gaps and adjust the scope as needs change. For a medical affairs consultant, this means being accountable not only for completing tasks but for showing how the work contributes to the company’s scientific and medical objectives. A strong outsourcing relationship therefore becomes easier to scale, refine and justify internally because both sides understand what success looks like.

How can medical affairs support scale across the product lifecycle?

Medical Affairs needs rarely remain static as a biotech asset progresses. In earlier development, external support may focus on understanding the scientific landscape, identifying evidence gaps, developing stakeholder and patient perspectives, and helping the company establish a practical Medical Affairs framework. At this stage, the priority is often to create enough structure and specialist support to prepare for future milestones without building a large fixed team too early.

As launch approaches, the workload can broaden quickly. Scientific materials, medical information processes, stakeholder engagement, education planning and cross-functional coordination may all need to mature at the same time. This is where capabilities such as medical education consulting can be integrated with wider Medical Affairs support rather than managed as a disconnected activity. Access to a medical education specialist can also help a lean biotech team add focused expertise for a defined period without creating a permanent role before the need is established.

After launch, priorities may shift again toward ongoing medical information, new evidence, evolving stakeholder questions, lifecycle activities and the interpretation of insights from real-world use. The outsourcing model should be able to change with these priorities rather than locking the company into a fixed service package. For biotech companies, this flexibility can be particularly valuable because development timelines, indications, markets and internal headcount may change rapidly. The strongest external partner is therefore one that can expand, narrow or reshape support while preserving continuity and keeping the work connected to the company’s Medical Affairs strategy.

Frequently asked questions

Choosing the right medical affairs support for your biotech company

The right medical affairs consultant can help a biotech company access specialised expertise, protect limited internal capacity and build Medical Affairs support around the needs of the product rather than around a fixed organisational model. The strongest outsourcing relationship is one that remains scientifically credible, clearly governed and flexible as priorities evolve.

Billev Pharma East supports biotech teams with Medical Affairs expertise across patient journey activities, medical education and medical inquiries, backed by broader capabilities in regulatory affairs, pharmacovigilance, clinical research and medical writing. If you are evaluating the best medical affairs outsourcing partners for biotech, contact Billev Pharma East to discuss where your team needs additional expertise and how our specialists can support your next Medical Affairs priority.

Sources: 1 – Medical Affairs Professional Society (MAPS). Competency Descriptions. 2025., 2 – Medical Affairs Professional Society (MAPS). Standards & Guidance: External Scientific Engagement. 2025., 3 – Medical Affairs Professional Society (MAPS). 2023 Medical Affairs Metrics Benchmark. 2023, 4 – Medical Affairs Professional Society (MAPS). Standards & Guidance: Operational Excellence. 2025, 5 – Medical Affairs Professional Society (MAPS). Evolving Role for Medical Affairs in Biopharmaceutical and MedTech.